Phio Pharmaceuticals Corp reports results for the quarter ended December 31 - Earnings Summary
01/04/2025 10:07
Phio Pharmaceuticals Corp PHIO.OQ reported a quarterly adjusted loss of 85 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-7.65. The lone analyst forecast for the quarter was for a loss of $1.23 per share. Reported revenue was zero; analysts expected zero. Phio Pharmaceuticals Corp's reported EPS for the quarter was a loss of 85 cents. The company reported a quarterly loss of $1.63 million. Phio Pharmaceuticals Corp shares had held steady so far this quarter and lost 27.8% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 65.8% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Phio Pharmaceuticals Corp is $4.00 This summary was machine generated from LSEG data April 1 at 09:06 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -1.23 | -0.85 | Beat |
| Sep. 30 2024 | -4.14 | -1.54 | Beat |
| Jun. 30 2024 | -4.59 | -3.62 | Beat |
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing